Protocol Ledger

NCT06076642 · Phase III · ACTIVE NOT RECRUITING

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Interventional Phase III clinical trial protocol NCT06076642 sponsored by Takeda in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-04 Enrollment: 53 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06076642
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)53 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06076642
Protocol FieldVerified Registry Value
NCT IdentifierNCT06076642
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment53 participants (ACTUAL)
Registered Start Date2024-11-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06076642
Hospital Research SiteLocationSite Profile
UCI Health and Chao Family Comprehensive Cancer CenterOrange, CAOpen Hospital Dossier ->
Montefiore Medical CenterThe Bronx, NYOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI